Aripiprazole (Abilify) vs Aripiprazole lauroxil (Aristada)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline

Aripiprazole (Abilify)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00712686 · Phase 3 · completed

A randomised, double-blind, active-controlled trial of aripiprazole (n=355) against olanzapine (n=348) in acute schizophrenia, with two co-primary objectives. The published results are mixed: olanzapine was statistically superior on PANSS efficacy at week 6, so aripiprazole did not show non-inferiority, while aripiprazole caused significantly less weight gain at week 26. The registry has no posted results; the figures are from the publication (Fleischhacker et al., Biol Psychiatry 2009).

Next expected readout: July 2030 · NCT06969755 (registry estimate)

Reported efficacy

The mean change in the PANSS Total Score (from baseline to Week 6); The percentage of patients showing significant weight gain (a≥ 7% increase) (from baseline to Week 26): Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05). (mixed)

Result source: NCT00712686

Aripiprazole lauroxil (Aristada)

Marketed by Alkermes plc

Approved in Schizophreniasmall molecule
Reliable signal

NCT01469039 · Phase 3 · completed

The trial was randomized, quadruple-blinded, and placebo-controlled, with 623 participants assigned to aripiprazole lauroxil 441 mg, 882 mg, or placebo. Its primary clinical symptom endpoint, change in PANSS total score at day 85, was significantly better with both active doses than with placebo (p<0.001 for each comparison).

Reported efficacy

The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39) (met)

Result source: NCT01469039

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAripiprazole (Abilify)Aripiprazole lauroxil (Aristada)
PANSS total, change-26.7 vs -21.2−5.5 vs placebo10 mg/day · wk 6 · n 99NCT00102063
31 other results
  • -28.6 vs -21.2 30 mg/day · wk 6 · n 97 · Phase 3 · primary NCT00102063
  • -19.4 vs -22.9 wk 6 · n 33 · Phase 3 · primary NCT02054702
  • -1.3 vs 4.8 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 4.7 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.7 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.8 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.9 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 4.9 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.1 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.2 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 5.4 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 5.8 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 6.2 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 5.6 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.7 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.8 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 5.9 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • -0.3 vs 6.1 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 6.1 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • -0.7 vs 5.6 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.6 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 5.5 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 4.5 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 3.9 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • -1.6 vs 3.7 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 2.9 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 1.6 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 1.8 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs -0.6 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.2 vs -0.3 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -7.7 vs -9.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
-21.8 vs -9.8−12 vs placebo882 mg · wk 12.14 · n 204NCT01469039
1 other result
  • -20.9 vs -9.8 441 mg · wk 12.14 · n 196 · Phase 3 · primary NCT01469039
CGI-S, change-1.2 vs -0.9−0.3 vs placebo10 mg/day · wk 6 · n 99NCT00102063
32 other results
  • -1.3 vs -0.9 30 mg/day · wk 6 · n 97 · Phase 3 · secondary NCT00102063
  • 0.1 vs 0.3 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.2 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0 vs 0.0 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.0 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
  • -1.3 vs -1.6 wk 6 · n 33 · Phase 3 · secondary NCT02054702
  • -0.1 vs -0.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
-0.5 vs -0.9+0.4 vs placebo441-441 mg · wk 52 · n 80NCT01626456
2 other results
  • -0.3 vs -0.9 882-882 mg · wk 52 · n 94 · Phase 3 · secondary NCT01626456
  • -0.2 vs -0.9 wk 52 · n 233 · Phase 3 · secondary NCT01626456
PANSS response—Not posted · NCT03485417—Not reported
PSP, change—Not posted · NCT03485417—Not reported
Relapse (% of patients)19.4% vs 37.5%−18.1 vs placebowk 52 · n 98NCT01149655
1 other result
  • 10% vs 39.6% wk 52 · n 269 · Phase 3 · secondary NCT00705783
—Not reported

PANSS total, change

Aripiprazole (Abilify)
-26.7 vs -21.2−5.5 vs placebo10 mg/day · wk 6 · n 99NCT00102063
31 other results
  • -28.6 vs -21.2 30 mg/day · wk 6 · n 97 · Phase 3 · primary NCT00102063
  • -19.4 vs -22.9 wk 6 · n 33 · Phase 3 · primary NCT02054702
  • -1.3 vs 4.8 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 4.7 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.7 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.8 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.9 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 4.9 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.1 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.2 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 5.4 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 5.8 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 6.2 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 5.6 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.7 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.8 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 5.9 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • -0.3 vs 6.1 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 6.1 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • -0.7 vs 5.6 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.6 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 5.5 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 4.5 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 3.9 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • -1.6 vs 3.7 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 2.9 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 1.6 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 1.8 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs -0.6 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.2 vs -0.3 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -7.7 vs -9.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
Aripiprazole lauroxil (Aristada)
-21.8 vs -9.8−12 vs placebo882 mg · wk 12.14 · n 204NCT01469039
1 other result
  • -20.9 vs -9.8 441 mg · wk 12.14 · n 196 · Phase 3 · primary NCT01469039

CGI-S, change

Aripiprazole (Abilify)
-1.2 vs -0.9−0.3 vs placebo10 mg/day · wk 6 · n 99NCT00102063
32 other results
  • -1.3 vs -0.9 30 mg/day · wk 6 · n 97 · Phase 3 · secondary NCT00102063
  • 0.1 vs 0.3 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.2 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0 vs 0.0 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.0 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
  • -1.3 vs -1.6 wk 6 · n 33 · Phase 3 · secondary NCT02054702
  • -0.1 vs -0.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
Aripiprazole lauroxil (Aristada)
-0.5 vs -0.9+0.4 vs placebo441-441 mg · wk 52 · n 80NCT01626456
2 other results
  • -0.3 vs -0.9 882-882 mg · wk 52 · n 94 · Phase 3 · secondary NCT01626456
  • -0.2 vs -0.9 wk 52 · n 233 · Phase 3 · secondary NCT01626456

PANSS response

Aripiprazole (Abilify)
—Not posted · NCT03485417
Aripiprazole lauroxil (Aristada)
—Not reported

PSP, change

Aripiprazole (Abilify)
—Not posted · NCT03485417
Aripiprazole lauroxil (Aristada)
—Not reported

Relapse (% of patients)

Aripiprazole (Abilify)
19.4% vs 37.5%−18.1 vs placebowk 52 · n 98NCT01149655
1 other result
  • 10% vs 39.6% wk 52 · n 269 · Phase 3 · secondary NCT00705783
Aripiprazole lauroxil (Aristada)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Aripiprazole (Abilify): 7 of 7 rows · Aripiprazole lauroxil (Aristada): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAripiprazole (Abilify)
Rows use multiple source trials
Aripiprazole lauroxil (Aristada)
Rows use multiple source trials
CGI-S
absolute change · score
No placebo or comparator arm
2.4 score @ 348wk10 - 30 mg QDa,b,c,d,e
NCT00239356 · Phase 3 · registry result, not featured evidence
show 1 more dose
NA score @ 348wk5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
-0.2 scoreb,c,d,e
NCT02634320 · Phase 4 · registry result, not featured evidence
2 other source trials
-0.1 scoreHigh
NCT01895452 · Phase 3 · registry result, not featured evidence
-0.1 scoreLow
NCT01895452 · Phase 3 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
-7.9 score @ 52wkc,d,e
NCT01942148 · Phase 3 · registry result, not featured evidence
1 other source trial
-3.55 score @ 52wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
-0.9 scoreHigha,c,d,e
NCT01895452 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.7 scoreLow
NCT01895452 · Phase 3 · registry result, not featured evidence
QLS Total
absolute change · score
No placebo or comparator arm
2.32 score @ 24wkb,c,d,e
NCT01959035 · Phase 3 · registry result, not featured evidence
0.4 scoreb,c,d,e
NCT02634320 · Phase 4 · registry result, not featured evidence
Dropout rate
20%f
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
39.7%
NCT01942148 · Phase 3 · registry result, not featured evidence
12.5%
NCT01959035 · Phase 3 · registry result, not featured evidence
32.4%
NCT01795547 · Phase 3 · registry result, not featured evidence
36.4%
NCT02054702 · Phase 3 · registry result, not featured evidence
—
NCT01149655 · Phase 3 · registry result, not featured evidence
—
NCT01432444 · Phase 3 · registry result, not featured evidence
20.6%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
40.2%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
45%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
—25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
84.7%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
37.8%
NCT00216476 · Phase 3 · registry result, not featured evidence
26.8%
NCT00102518 · Phase 3 · registry result, not featured evidence
16%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
17.6%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
14.6%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
20%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
22.9%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
11.1%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
26.3%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
6.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
16.7%
NCT01338298 · Phase na · registry result, not featured evidence
35.1%882 mgg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
37.2%441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.8%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.8%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
31.4%
NCT02634320 · Phase 4 · registry result, not featured evidence
12.4%High
NCT01895452 · Phase 3 · registry result, not featured evidence
6.2%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—f
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
5.9%
NCT01942148 · Phase 3 · registry result, not featured evidence
5.7%
NCT01959035 · Phase 3 · registry result, not featured evidence
10.8%
NCT01795547 · Phase 3 · registry result, not featured evidence
3%
NCT02054702 · Phase 3 · registry result, not featured evidence
—
NCT01149655 · Phase 3 · registry result, not featured evidence
—
NCT01432444 · Phase 3 · registry result, not featured evidence
2.9%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
6.2%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
0%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
—25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
8.2%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
2.2%
NCT00216476 · Phase 3 · registry result, not featured evidence
—
NCT00102518 · Phase 3 · registry result, not featured evidence
7%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
3.9%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
12.2%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6.7%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
2.9%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
—30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—
NCT01338298 · Phase na · registry result, not featured evidence
—882 mgg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
—441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
7.3%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
1.8%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.9%
NCT02634320 · Phase 4 · registry result, not featured evidence
1.8%High
NCT01895452 · Phase 3 · registry result, not featured evidence
1.5%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Serious AEs
0%f
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
10.3%
NCT01942148 · Phase 3 · registry result, not featured evidence
3.4%
NCT01959035 · Phase 3 · registry result, not featured evidence
8.3%
NCT01795547 · Phase 3 · registry result, not featured evidence
3%
NCT02054702 · Phase 3 · registry result, not featured evidence
3.1%
NCT01149655 · Phase 3 · registry result, not featured evidence
14.2%
NCT01432444 · Phase 3 · registry result, not featured evidence
8.8%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
0%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
13.4%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
5.7%300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
8.4%25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
12.9%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
4.1%Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
15.6%
NCT00216476 · Phase 3 · registry result, not featured evidence
6.2%
NCT00102518 · Phase 3 · registry result, not featured evidence
4%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
3.9%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
4.9%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6.7%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
0%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%
NCT01338298 · Phase na · registry result, not featured evidence
1.9%882 mgg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
1.4%441 mg
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
4.1%ALKS 9072, High
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
0%ALKS 9072, Low
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
9.8%
NCT02634320 · Phase 4 · registry result, not featured evidence
1.8%High
NCT01895452 · Phase 3 · registry result, not featured evidence
0%Low
NCT01895452 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
f
eye irritation/swelling 6.3% (placebo 0%)
psychiatric decompensation 6.3% (placebo 0%)
psychiatric decompensation 6.3% (placebo 0%)
NCT00345033 · Phase 4 · registry result, not featured evidence
show 27 more results
nasopharyngitis 45.6%
somnolence 20.6%
nausea 17.6%
NCT01942148 · Phase 3 · registry result, not featured evidence
weight increased 6.8%
NCT01959035 · Phase 3 · registry result, not featured evidence
accidental overdose 20.8%
insomnia 11.8%
weight increased 9%
NCT01795547 · Phase 3 · registry result, not featured evidence
akathisia 21.2%
headache 12.1%
constipation 9.1%
NCT02054702 · Phase 3 · registry result, not featured evidence
schizophrenia 9.2% (placebo 16.7%)
weight increased 8.2% (placebo 10.4%)
nasopharyngitis 7.1% (placebo 2.1%)
NCT01149655 · Phase 3 · registry result, not featured evidence
insomnia 6.7%
akathisia 6.3%
weight increased 2.3%
NCT01432444 · Phase 3 · registry result, not featured evidence
400/300 mg IM Depot
headache 7.6%
nasopharyngitis 7%
anxiety 6.8%
NCT00731549 · Phase 3 · registry result, not featured evidence
5 - 30 mg QD
pyrexia 35%
headache 30%
cough 15%
NCT00239356 · Phase 3 · registry result, not featured evidence
10 - 30 mg QD
back pain 7.2%
anxiety 6.2%
headache 6.2%
NCT00239356 · Phase 3 · registry result, not featured evidence
300 or 400 mg
insomnia 11.7%
akathisia 10.6%
headache 9.8%
NCT00706654 · Phase 3 · registry result, not featured evidence
25 or 50 mg
insomnia 13.7%
back pain 11.5%
weight decreased 9.2%
NCT00706654 · Phase 3 · registry result, not featured evidence
headache 15.3%
influenza 10.6%
weight increased 10.6%
NCT01001702 · Phase 3 · registry result, not featured evidence
insomnia 10% (placebo 9%)
weight increased 9.7% (placebo 9.7%)
anxiety 5.9% (placebo 7.5%)
NCT00705783 · Phase 3 · registry result, not featured evidence
insomnia 24.4%
anxiety 15.6%
headache 11.1%
NCT00216476 · Phase 3 · registry result, not featured evidence
extrapyramidal disorder 14.8%
somnolence 12.9%
headache 9.5%
NCT00102518 · Phase 3 · registry result, not featured evidence
10 mg/day
headache 16% (placebo 10%)
extrapyramidal disorder 13% (placebo 5%)
insomnia 11% (placebo 15%)
NCT00102063 · Phase 3 · registry result, not featured evidence
30 mg/day
extrapyramidal disorder 21.6% (placebo 5%)
somnolence 21.6% (placebo 6%)
tremor 11.8% (placebo 2%)
NCT00102063 · Phase 3 · registry result, not featured evidence
24-30 mg/day
nausea 22%
insomnia 17.1%
salivary hypersecretion 14.6%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6-12 mg/day
insomnia 20%
somnolence 20%
epistaxis 13.3%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
2 mg/day
nausea 20%
insomnia 14.3%
nasopharyngitis 14.3%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
400 mg
injection site pain 35.3%
headache 23.5%
akathisia 17.6%
NCT01646827 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 27.8%
headache 22.2%
akathisia 16.7%
NCT01646827 · Phase 1 · registry result, not featured evidence
400mg
injection site pain 6.7%
toothache 6.7%
blood creatine phosphokinase increased 5%
NCT01552772 · Phase 1 · registry result, not featured evidence
30 mg
headache 50%
sedation 33.3%
abdominal pain upper 16.7%
NCT00102479 · Phase 1 · registry result, not featured evidence
25 mg
abdominal pain upper 42.9%
acne 28.6%
dizziness 28.6%
NCT00102479 · Phase 1 · registry result, not featured evidence
20 mg
headache 50%
insomnia 25%
musculoskeletal stiffness 25%
NCT00102479 · Phase 1 · registry result, not featured evidence
nausea 50% (placebo 22.2%)
vomiting 50% (placebo 38.9%)
diarrhea 45% (placebo 38.9%)
NCT01338298 · Phase na · registry result, not featured evidence
882 mgg
insomnia 12% (placebo 11.6%)
akathisia 11.1% (placebo 4.3%)
headache 8.7% (placebo 8.2%)
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 6 more results
441 mg
akathisia 11.6% (placebo 4.3%)
insomnia 9.7% (placebo 11.6%)
headache 8.2% (placebo 8.2%)
NCT01469039 · Phase 3 · monotherapy · Schizophrenia · phase 3
insomnia 10.1%
weight increased 4.6%
headache 3%
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
headache 6.4%
weight increased 6.4%
insomnia 2.7%
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
anxiety 5.9%
NCT02634320 · Phase 4 · registry result, not featured evidence
High
insomnia 7.1%
nasopharyngitis 4%
diarrhoea 3.1%
NCT01895452 · Phase 3 · registry result, not featured evidence
Low
diarrhoea 6.2%
nasopharyngitis 6.2%
toothache 6.2%
NCT01895452 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 4.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aripiprazole (Abilify)

Total Cholesterol Change mg/dL -15.3 vs 5.6 placebo mg/dL @ 8wk
absolute change · mg/dL
NCT00345033 · Phase 4 · registry result, not featured evidence
Weight -1.5 vs 0.3 placebo kg @ 8wk
absolute change · kg
NCT00345033 · Phase 4 · registry result, not featured evidence
BMI -0.52 vs 0.03 placebo kg @ 8wk
absolute change · kg
NCT00345033 · Phase 4 · registry result, not featured evidence
Insulin Sensitivity 0.003 vs -0.005 placebo minutes @ 8wk
absolute change · minutes
NCT00345033 · Phase 4 · registry result, not featured evidence
Triglyceride Change mg/dL -5.9 vs -7.3 placebo mg/dL @ 8wk
absolute change · mg/dL
NCT00345033 · Phase 4 · registry result, not featured evidence
HOMA-IR 0.6 vs 0.65 placebo score @ 8wk
absolute change · score
NCT00345033 · Phase 4 · registry result, not featured evidence
CGAS 8.6 score @ 6.14wk24-30 mg/day
absolute change · score
No placebo or comparator arm
NCT01942161 · Phase 2/3 · registry result, not featured evidence
show 3 more results
8.5 score @ 6.14wk6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
10.5 score @ 6.14wk2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
5.6 score @ 52wk
NCT01942148 · Phase 3 · registry result, not featured evidence
SWN-K Total 0.19 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01959035 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.57 score @ 12wk
NCT01959035 · Phase 3 · registry result, not featured evidence
QLS Total 7.47 vs 2.8 Paliperidone score @ 28wk
absolute change · score
NCT01795547 · Phase 3 · registry result, not featured evidence
SWN-K Total 4.82 vs 3.81 Paliperidone score @ 28wk
absolute change · score
NCT01795547 · Phase 3 · registry result, not featured evidence
Cognitive Composite Z Score -0.024 vs 0.045 Brexpiprazole Z-score @ 6wk
absolute change · Z-score
NCT02054702 · Phase 3 · registry result, not featured evidence
show 1 more result
0.113 vs -0.01 Brexpiprazole Z-score @ 6wk
NCT02054702 · Phase 3 · registry result, not featured evidence
CGI-I 2.7 vs 2.5 Brexpiprazole score @ 6wk
absolute change · score
NCT02054702 · Phase 3 · registry result, not featured evidence

+ 49 further endpoints in the CSV export.

Aripiprazole lauroxil (Aristada)

PANSS Total -10 vs -19.1 placebo score @ 52wk441-441 mg
absolute change · score
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-8.3 vs -19.1 placebo score @ 52wk882-882 mg
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-5.9 vs -19.1 placebo score @ 52wk
Total Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Positive Subscale -3.4 vs -5.8 placebo score @ 52wk441-441 mg
absolute change · score
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-2.3 vs -5.8 placebo score @ 52wk882-882 mg
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.8 vs -5.8 placebo score @ 52wk
Positive Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS Negative Subscale -1.5 vs -4.1 placebo score @ 52wk441-441 mg
absolute change · score
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-2.1 vs -4.1 placebo score @ 52wk882-882 mg
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-1.2 vs -4.1 placebo score @ 52wk
Negative Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
PANSS General Psychopathology -5.1 vs -9.2 placebo score @ 52wk441-441 mg
absolute change · score
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 2 more results
-4 vs -9.2 placebo score @ 52wk882-882 mg
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
-2.9 vs -9.2 placebo score @ 52wk
General Psychopathology Subscale Score
NCT01626456 · Phase 3 · monotherapy · Schizophrenia · phase 3
BPRS Total -2.7 score
absolute change · score
No placebo or comparator arm
NCT02634320 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify)'s landscape · Aripiprazole lauroxil (Aristada)'s landscape